...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and experimental pharmacology & physiology >Inhibition of the renal renin-angiotensin system and renoprotection by pitavastatin in type1 diabetes.
【24h】

Inhibition of the renal renin-angiotensin system and renoprotection by pitavastatin in type1 diabetes.

机译：匹伐他汀在1型糖尿病中的肾肾素-血管紧张素系统抑制作用和肾保护作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

1. The aim of the present study was to investigate whether or not pitavastatin ameliorates diabetic nephropathy and if inhibition of the rennin-angiotensin-aldosterone system (RAAS) is associated with any renoprotective effects. Pitavastatin (10mg/ kg/day) and/or spironolactone (100mg/kg/day) were given by gavage for 3weeks to uninephrectomized rats with streptozotocin-induced diabetes. 2. Pitavastatin or spironolactone significantly reduced proteinuria and collagen deposition, and normalized creatinine clearance, serum creatinine levels and blood urea nitrogen concentrations. 3. Reverse transcription polymerase chain reaction analysis showed that the renal expression of collagenI, transforming growth factor-beta and monocyte chemoattractant-1 were increased in diabetic rats and reduced by the pitavastatin and/or spironolactone treatment. 4. These agents also decreased angiotensin converting enzyme expression and aldosterone concentrations in the renal homogenate, but had no effect on blood glucose, haemoglobinA(1c) , and plasma total cholesterol, Na(+) , K(+) , aldosterone and NOx levels, or on systolic blood pressure measured by the tail-cuff method. Interestingly, cotreatment with pitavastatin and spironolactone did not result in additional normalization. 5. These results suggest that pitavastatin shows renoprotective effects against diabetic nephropathy mediated in part by inhibition of the renal RAAS, including the suppression of angiotensin-converting enzyme expression and aldosterone production.
机译：1.本研究的目的是研究匹伐他汀是否可改善糖尿病性肾病，以及抑制肾素-血管紧张素-醛固酮系统（RAAS）是否与任何肾脏保护作用有关。将匹他伐他汀（10mg / kg /天）和/或螺内酯（100mg / kg /天）灌胃3周，给未进行过直肠切除的链脲佐菌素诱发的糖尿病大鼠服用。 2.匹伐他汀或螺内酯可显着降低蛋白尿和胶原蛋白沉积，并使肌酐清除率，血清肌酐水平和血尿素氮浓度正常化。 3.逆转录聚合酶链反应分析显示，糖尿病大鼠的胶原蛋白I，转化生长因子-β和单核细胞趋化因子-1的肾脏表达增加，而匹伐他汀和/或螺内酯处理降低了肾脏的表达。 4.这些药物还降低了肾匀浆中血管紧张素转化酶的表达和醛固酮浓度，但对血糖，血红蛋白A（1c）和血浆总胆固醇，Na（+），K（+），醛固酮和NOx水平没有影响，或通过尾套法测量的收缩压。有趣的是，用匹伐他汀和螺内酯共同治疗不会导致额外的正常化。 5.这些结果表明匹伐他汀对糖尿病性肾病具有部分通过抑制肾RAAS介导的肾脏保护作用，包括抑制血管紧张素转化酶的表达和醛固酮的产生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号